TY  - GEN
N2  - "In view of concerns in the biomedical research community, the National Institutes of Health proposed a set of agency principles as well as operational guidelines encouraging recipients of NIH funding to more effectively promote the wider distribution of research materials or 'tools' without the restrictions imposed through the patenting and exclusive licensing of these materials. In December 1999, the NIH issued its Final Notice, which articulates the agency's funding policies relating to the commercialisation of research results and materials. These revisions to its previous proposal demonstrate that NIH is taking cautious steps to promote research, while attempting to respect the competing concerns of the bio-medical research and commercialisation communities. NIH may need to pay particular attention to the potentially adverse consequences that an aggressive implementation of this policy may have on small businesses that commercialise 'research tools' that arise from NIH funding. Whether NIH's policy will promote research or chill private investment in new biotechnology research should be very closely evaluated".
AB  - "In view of concerns in the biomedical research community, the National Institutes of Health proposed a set of agency principles as well as operational guidelines encouraging recipients of NIH funding to more effectively promote the wider distribution of research materials or 'tools' without the restrictions imposed through the patenting and exclusive licensing of these materials. In December 1999, the NIH issued its Final Notice, which articulates the agency's funding policies relating to the commercialisation of research results and materials. These revisions to its previous proposal demonstrate that NIH is taking cautious steps to promote research, while attempting to respect the competing concerns of the bio-medical research and commercialisation communities. NIH may need to pay particular attention to the potentially adverse consequences that an aggressive implementation of this policy may have on small businesses that commercialise 'research tools' that arise from NIH funding. Whether NIH's policy will promote research or chill private investment in new biotechnology research should be very closely evaluated".
T1  - Sharing biomedical research resources :Principles and guidelines for recipients of NIH research grants and contracts : Race horse or trojan horse? : Proposed restrictions on the commercialisation of "research tools" by the National Institutes of Health /
AU  - Mays, Thomas D.,
VL  - 1999/2000 No 2 pages 56-66
ID  - 12145
KW  - Patents.
KW  - UNIVERSITY TECHNOLOGY TRANSFER PROGRAMMES
KW  - PATENTS : PATENTABILITY : SCIENTIFIC AND TECHNICAL PROGRESS, RESEARCH AND DEVELOPMENT (RD)
KW  - BIOMEDICAL RESEARCH : GUIDELINES
KW  - NATIONAL INSTITUTES OF HEALTH (NIH) : RECOMMENDATIONS : BIOMEDICAL RESEARCH TOOLS
TI  - Sharing biomedical research resources :Principles and guidelines for recipients of NIH research grants and contracts : Race horse or trojan horse? : Proposed restrictions on the commercialisation of "research tools" by the National Institutes of Health /
ER  -